Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection - Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection

开始日期2021-04-20

申办/合作机构-

JPRN-jRCT2063200047 / Completed临床2期IIT

A single-center, exploratory clinical trial evaluating the safety and efficacy of CL2020 in patients with amyotrophic lateral sclerosis - A single-center, exploratory clinical trial evaluating the safety and efficacy of CL2020 in patients with amyotrophic lateral sclerosis

开始日期2021-02-16

申办/合作机构-

NCT04261335 / Completed临床1期IIT

The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial

The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will evaluate the efficacy of CL2020 cells for infant development.

开始日期2020-03-04

申办/合作机构

Nagoya University

[+1]

100 项与 Nafimestrocel 相关的临床结果

登录后查看更多信息

100 项与 Nafimestrocel 相关的转化医学

登录后查看更多信息

100 项与 Nafimestrocel 相关的专利（医药）

登录后查看更多信息

项与 Nafimestrocel 相关的文献（医药）

2024-11-12·Stem Cells Translational Medicine

Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)

Article

作者: Yamamoto, Toshimichi ; Sato, Yoshiaki ; Nishimura, Chiho ; Saito, Akiko ; Tanaka, Taihei ; Sugiyama, Yuichiro ; Kobayashi, Yumiko ; Oshiro, Makoto ; Matsuyama, Nao ; Kinoshita, Fumie ; Hayashi, Seiji ; Suzuki, Sakiko ; Aoyama, Aiko ; Shoji, Go ; Ando, Masahiko ; Miura, Ryosuke ; Goto, Ryoko ; Ueda, Kentaro ; Tanaka, Ryuichi ; Iwata, Osuke ; Muramatsu, Kanji ; Mizuno, Masaaki ; Ito, Miharu ; Tanahashi, Yoshihiro ; Hayakawa, Masahiro ; Fujita, Yumi ; Kotani, Atsuna ; Suzuki, Toshihiko ; Taniguchi, Akinobu ; Matsui-Hirai, Hisako ; Shimizu, Shinobu ; Muramatsu, Yukako ; Katayama, Akemi ; Tanimura, Tomoshige ; Hayashi, Naoko ; Suetake, Yukihiro ; Ikari, Azuma ; Tsuda, Kennosuke ; Yue, Xu ; Ueda, Kazuto ; Hirakawa, Akihiro ; Kato, Yuichi ; Sahashi, Takeshi ; Kanzawa, Takahiro ; Uchizono, Hiromasa ; Yoshikane, Masatoshi ; Kawase, Koya ; Kidokoro, Hiroyuki ; Watarai, Yasuko ; Hattori, Tetsuo ; Hashimoto, Yuki

Abstract:

Hypoxic–ischemic encephalopathy (HIE), associated with high mortality and neurological sequelae, lacks established treatment except therapeutic hypothermia. Clinical-grade multilineage-differentiating stress-enduring (Muse) cells (CL2020) demonstrated safety and efficacy in nonclinical HIE rat models, thereby leading to an investigator-initiated clinical trial to evaluate CL2020 safety and tolerability in neonatal HIE as a single-center open-label dose-escalation study with 9 neonates with moderate-to-severe HIE who received therapeutic hypothermia. Each patient received a single intravenous injection of CL2020 cells between 5 and 14 days of age. The low-dose (3 patients) and high-dose (6 patients) groups received 1.5 × 106 and 1.5 × 107 cells/dose, respectively. The occurrence of any adverse event within 12 weeks following CL2020 administration was the primary endpoint of this trial. No significant changes in physiological signs including heart rate, blood pressure, and oxygen saturation were observed during or after administration. The only adverse event that may be related to cell administration was a mild γ-glutamyltransferase level elevation in one neonate, which spontaneously resolved without any treatment. All patients enrolled in the trial survived, and normal developmental quotients (≥ 85) in all 3 domains of the Kyoto Scale of Psychological Development 2001 were observed in 67% of the patients in this trial. CL2020 administration was demonstrated to be safe and tolerable for neonates with HIE. Considering the small number of patients, a randomized controlled confirmatory study is warranted to verify these preliminary findings and evaluate the efficacy of this therapy.

Stem Cell Research & Therapy

Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

Article

作者: Kumagai, Gentaro ; Imagama, Shiro ; Funayama, Toru ; Kamei, Naosuke ; Nagata, Keiji ; Suzuki, Shinsuke ; Nakashima, Hiroaki ; Ito, Sadayuki ; Yamato, Yu ; Harmon Matsumoto, Satoko ; Inami, Satoshi ; Suda, Kota ; Yamazaki, Masashi ; Koda, Masao ; Inoue, Gen ; Furuya, Takeo ; Yamada, Hiroshi ; Ouchida, Jun ; Nishida, Norihiro ; Komatsu, Miki ; Segi, Naoki ; Nakamae, Toshio ; Ueda, Haruki ; Funaba, Masahiro ; Endo, Toshiki ; Miyagi, Masayuki ; Takahashi, Hiroshi ; Takaso, Masashi ; Suzuki, Hidenori

Abstract:

Introduction:

Spinal cord injury (SCI) is a devastating injury and remains one of the largest medical and social burdens because of its intractable nature. According to the recent advances in stem cell biology, the possibility of spinal cord regeneration and functional restoration has been suggested by introducing appropriate stem cells. Multilineage-differentiating stress enduring (Muse) cells are a type of nontumorigenic endogenous reparative stem cell. The positive results of Muse cell transplantation for SCI was shown previously. As a first step for clinical application in human SCI, we conducted a clinical trial aiming to confirm the safety and feasibility of intravenously injected donor-Muse cells.

Methods:

The study design of the current trial was a prospective, multicenter, nonrandomized, nonblinded, single-arm study. The clinical trial registration number was JRCT1080224764. Patients with a cervical SCI with a neurological level of injury C4 to C7 with the severity of modified Frankel classification B1 and B2 were included. A primary endpoint was set for safety and feasibility. Our protocol was approved by the PMDA, and the trial was funded by the Life Science Institute, Tokyo, Japan. The present clinical trial recruited 10 participants (8 males and 2 females) with an average age of 49.3 ± 21.2 years old. All 10 participants received a single dose of allogenic CL2020 (a total of 15 × 106 cells, 2.1–2.7 × 105 cells/kg of body weight), which is a Muse cell-based product produced from human mesenchymal stem cells, by an intravenous drip.

Results:

There were two reported severe adverse events, both of which were determined to have no causal relationship with Muse cell treatment. The change in the ISNCSCI motor score, the activity of daily living and quality of life scores showed statistically significant improvements compared to those data at the time of CL2020 administration.

Conclusion:

In the present trial, no safety concerns were identified, and Muse cell product transplantation demonstrated good tolerability. Future clinical trials with appropriate study designs incorporating a control arm will clarify the definitive efficacy of single-dose allogenic Muse cell treatment with intravenous administration to treat SCI.Trial registration: jRCT, JRCT1080224764. Registered 03 July 2019, https://jrct.niph.go.jp/latest-detail/jRCT1080224764.

项与 Nafimestrocel 相关的新闻（医药）

2024-01-27

·生物制品圈

蔡磊再捐助1亿元抗击渐冻症，此前称“离死亡非常近了”，治疗渐冻症为何这么难？

导读1月27日，知名渐冻症抗争者蔡磊宣布，“我与夫人将再捐助1亿元，用于支持渐冻症的基础研究、药物研发、临床医疗等科研项目。”“盼望脑科学和神经系统疾病、免疫学、代谢组学、蛋白组学、基因和转录组学、干细胞、声光电磁、CDMO、CRO、人工智能和传统医学等研究方向的科学家、医生、生物医药公司和关注神经系统疾病研究的临床医院等机构和个人能积极与我们联系，同时也欢迎有情怀、有决心的人士加入团队。”就在前几天，蔡磊坦言，“离死亡已经非常近了”。不管是热心的医生、科学家，还是遇到诸多江湖骗子推荐的“偏方”，都没有帮助他缓和疾病。“从起床到卫生间，5米的距离都需要有人扶着……吞咽、包括咳痰都咳不出来了，呼吸也在下滑，我现在是整夜戴着呼吸机，抬头也抬不起来了”。一直以来，渐冻症都被视作一种可怕的神经系统疾病，然而这样的一种疾病，目前临床上却缺乏良好的治疗手段。近两年，有关渐冻症治疗研究也在稳步开展，人类距离攻克渐冻症还有多远？今天，知名渐冻症患者蔡磊宣布，他们夫妇二人捐助1亿元攻克渐冻症。然而就在上周，蔡磊称自己的病情正在恶化，没有得到缓解，呼吸、吞咽困难，“离死亡已经非常近了”。渐冻症的治疗为何这么难？目前有哪些药物可用来治疗和缓解这种可怕的疾病。01知名渐冻症的抗争者：蔡磊 1月18日，前京东副总裁、知名渐冻症抗争者蔡磊接受了媒体采访，分享了自己近期身体的状况。在采访中我们得知，目前蔡磊的身体机能每况愈下，吞咽、咳痰都变得困难，甚至连最基本的呼吸功能都在急速下滑。去年10月，蔡磊接受了一款实验药物，在用药后表示该药物给他带来了明显的初期效果，具体表现在“腿部力量、说话都有改善”。然而，这种药效仅持续了一个多月。在那之后，他的身体状况不仅没有得到改善，反而比用药之前更为恶化。生理机能的不断下滑让他意识到，“自己离死亡已经非常近了”。可以说，在确诊渐冻症后，蔡磊表现出了非常顽强勇敢的一面，时刻都在与死亡、疾病做斗争。在确诊渐冻症之前，蔡磊任职京东副总裁，家庭美满幸福，当前广泛使用的“电子发票”就出自他的发明。然而，不幸总是来得猝不及防，2018年，蔡磊突然发现小臂肌肉会时不时持续性颤动，一开始他以为是自己工作太累所致，作为“工作狂”的他并没有太在意，直到这种现象持续了一年多。年轻时候的蔡磊后来他才发现自己患上了一种罕见病——渐冻症。这些年，蔡磊为了能够治疗渐冻症，至少花费1000万元，尝试了不少药物和治疗方法，包括全球首款获FDA批准用于治疗渐冻症的药物利鲁唑（Riluzole），这是一种口服片剂，通过抑制神经递质谷氨酸的释放来达到减缓病情发展的作用。只是该药物作用机制不明显，效果不够显著；除此之外，蔡磊还尝试了依达拉奉（Edaravone），这是2017年FDA批准用于治疗中风的老药，同样目前机制尚不清楚。除了治疗渐冻症的传统药物外，蔡磊还不惜以身试药，亲自尝试一些还在试验阶段的新药，并且花大笔资金投资渐冻症这一“孤儿药物”。 12月27日，蔡磊创办的“破冰驿站”公布了一则抗渐冻症药物的最新信息：北京大学第三医院神经内科樊东升主任团队、清华大学贾怡昌教授及神济昌华团队与蔡磊科研团队分享了SNUG01渐冻症药物研发进展和第一例同情给药六个月情况。此外，蔡磊也尝试了多种中医中药以及各类民间神医偏方，但都无法取得好的疗效。或许正是在渐冻症特效药和临床治疗手段上的“上下求索”，有媒体因此将蔡磊称呼为“猎药病人”。那么问题来了，人类到底还要多久才能破译渐冻症呢？02渐冻症的可怕之处：慢慢困住躯体渐冻症的全称是肌萎缩侧索硬化症（ALS），是一种影响运动神经元的神经系统疾病。运动神经元是大脑和脊髓中控制随意肌肉运动和呼吸的神经细胞。当运动神经元退化和死亡时，它们会停止向肌肉发送信息，这会导致肌肉变弱、抽搐和萎缩。最终，渐冻症患者的大脑会失去启动和控制自主运动的能力，如行走、说话、咀嚼和其他功能，以及呼吸。图源：verywell health肌萎缩侧索硬化症是渐进性的，这意味着症状会随着时间的推移而恶化。目前，渐冻症的引发机制分为家族性和散发性两种，大约10%的渐冻症病例是家族性，已发现十几种基因与该疾病相关。大约25-40%的家族性病例（以及一小部分散发病例）是由C9orf72基因缺陷引起的，另有12-20%的家族性病例由SOD1基因突变引起。而剩下几乎所有的病例都是散发性的，蔡磊患的渐冻症便是散发性疾病，这意味着这种疾病似乎是随机发生的，没有明确相关的危险因素，也没有该疾病的家族史。也正是这种特殊的发病机理，决定了渐冻症药物研发的研发之路犹如大海捞针般困难。03最新的有关渐冻症的治疗进展当前，有关渐冻症的治疗研究动向大致有以下几个方面：第一、特效药的研发这是渐冻症治疗的主要手段之一。在过去，渐冻症药物主要有利鲁唑（Riluzole）和依达拉奉（Edaravone），这两种药物被认为有延缓渐冻症的效果，但并不是治愈性的。近两年，有关渐冻症特效药的研发也在稳步开展。去年9月，NIH宣布对两种渐冻症药物疗法提供资金支持：一款药物是由生物技术公司Prilenia Therapeutics研发的普利多匹定（Prilenia Therapeutics）。这一种激活Sigma-1受体的小分子药物，该受体存在于神经元上。目前该药物已在试验阶段，计划在美国45个临床站点招募200名患者，旨在研究药物的安全性和有效性。另一款药物是由Clene Nanomedicine研发的、名为CNM-Au8（Clene Nanomedicine）的口服悬浮液，该药物由金纳米晶体制成，可以通过提高细胞中能量分子水平来保护神经元。目前该药物试验计划在10个临床站点招募100名患者，研究药物的安全性和有效性。第二、细胞疗法近两年，BrainStorm Cell Therapeutics公司的干细胞疗法NurOwn颇为引人注目。这种方法旨在从患者的骨髓中提取间充质干细胞（MSC），经过培养后使其成为能够产生高水平神经营养因子（NTF）细胞，之后注射进人的体内，对大脑和脊髓起到神经修复作用。尽管这一疗法看起来颇有希望，然而却受到了FDA质疑：去年9月，FDA工审查员对BrainStorm Cell的疗法表示担忧，审查员在简报文件中表示，“它认为没有足够的证据支持NurOwn的临床益处，并补充说存在大量缺失的数据”。该消息一出，BrainStorm Cell Therapeutics公司股价在早盘交易中下跌近40.4%。同年9月，Rapa Therapeutics和马萨诸塞州总医院的研究人员共同领导了一项名为RAPA-501的研究。在研究中，研究人员旨在用一种减少炎症的细胞疗法减缓渐冻症疾病进展。试验计划在七个临床地点招募40名患者，将使用标准方法和机器学习算法来检查治疗效果。第三、干细胞疗法今年1月，三菱化学旗下的生命科学研究所利用一种名为CL2020的基于干细胞的疗法进行了2期研究，CL2020的治疗方法包括将一种特殊类型的耐压干细胞直接注射到患者的血液中。这种干细胞疗法的目标是改善患者的身体机能，但研究结果显示其效果并不显著。来源：ALS News Today 第四、蛋白质疗法去年8月，南卡罗来纳医科大学霍林斯癌症中心的研究人员在《衰老细胞》（Aging Cell）杂志上发表研究，从蛋白质的角度去解析渐冻症。该研究团队发现，缺乏一种名为P17/PERMIT的蛋白质的老年小鼠表现出与肌萎缩侧索硬化症（ALS）患者相似的神经功能异常。研究人员指出，这种蛋白质缺乏导致受损线粒体的积累，从而影响运动功能。之后研究团队使用一种药物，可以触发受损线粒体的破坏，治疗这些小鼠，从而恢复了它们的运动功能，这或许为渐冻症治疗提供了一个全新的思路。第五、基因疗法北京大学第三医院神经内科樊东升主任团队、清华大学贾怡昌教授及神济昌华团队与蔡磊科研团队合作研发了一款名为SNUG01的基因治疗药物，旨在一次给药，长期作用。去年11月，该药物在北医三院完成首例受试者给药。去年12月月底，樊东升向媒体透露，第一例同情给药十分乐观。事实上，作为罕见病的一种，渐冻症的相关的药物研究一直不是大热门，再加上其病理机制比较复杂、缺乏清晰的靶点和生物标志物、大脑血脑屏障等因素，相关研究更是难上加难。别说破译渐冻症，当下连减缓渐冻症的药物都遥不可及。我们只能寄希望于未来，等待医疗技术的发展，终有一日破译渐冻症。参考资料1.渐冻症患者蔡磊接受同情用药，北医三院/清华大学团队表示“情况十分乐观”.深究科学.2.蔡磊：猎药病人引发的震荡丨世界渐冻人日特稿.南方周末.3.世界渐冻人日｜200年上市4款药，“渐冻人”何时能解冻？.澎湃新闻.4.Amyotrophic Lateral Sclerosis (ALS).NIH.5.FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy.reuters.6.Stem cell-based therapy deemed safe in Phase 2 study.ALS News Today.7.神济昌华渐冻症AAV基因治疗药物SNUG01于北医三院完成首例受试者给药.神济昌华. 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

高管变更

2023-01-26

·PRNewswire

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032) | Assesses DelveInsight

Considering the expected launch of new upcoming therapies and greater integration of early patient screening, it can be safely assumed that the MI market will undergo a paradigm shift in the present decade holding new prospects and opportunities for those planning to carve out their niche during the forecast period [2022–2032] LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's MI Market Insights report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the MI Market Report As per DelveInsight analysis, the MI market size in the 7MM was approximately USD 21 billion in 2021 According to the assessment done by DelveInsight, the estimated total MI diagnosed prevalent cases in the 7MM was approximately 15 million in 2021 Leading MI companies such as AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others are developing novel MI drugs that can be available in the MI market in the coming years The promising MI therapies in the pipeline include FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC , and others In November 2022, Amgen presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine As per the Q32022 investor presentation of AstraZeneca data, readouts from the Phase III (DAPA-MI) trial of FARXIGA/FORXIGA is anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023 In June 2021, Idorsia announced the initiation of the Phase III registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI In September 2020, the FDA granted Fast Track designation for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI In July 2020, AstraZeneca was granted Fast Track designation in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack Discover which therapies are expected to grab the major MI market share @ MI Market Report. MI Overview MI is pathologically defined as myocardial cell death caused by prolonged ischemia. The first ultrastructural changes are diminished cellular glycogen, relaxed myofibrils, and sarcolemmal disruption, which can be seen as early as 10-15 minutes after the onset of ischemia. Symptoms of MI include chest pain, which may initially manifest as a sensation of tightness or pressure. The pain usually radiates to the left arm, but it can also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Sweating, nausea, vomiting, and fainting may accompany chest pain. The typical clinical features, ECG findings, and elevation of cardiac biomarkers are used for MI diagnosis. Cardiovascular catheterization is required for definitive diagnosis and serves diagnostic and therapeutic purposes. All patients suspected of having ACS should be considered for emergency revascularization; other MI treatment options include anticoagulation, antiplatelet therapy, statin therapy, and other adjunctive measures. MI Epidemiology Segmentation DelveInsight estimates that there were approximately 15 million diagnosed prevalent cases of MI in the 7MM in 2021. Among EU4 countries, Germany had the highest number of diagnosed prevalent cases of MI, while Spain had the lowest prevalent population among the 7MM. The MI market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Diagnosed Prevalent Cases Gender-specific Prevalence Type-specific Prevalence Download the report to understand which factors are driving MI epidemiology trends @ MI Epidemiological Insights. MI Treatment Market The goals of initial MI treatment are to relieve pain, immediately identify ST changes via 12-lead EKG, initiate reperfusion (if the patient is a candidate), and assess and treat hemodynamic abnormalities. Oxygen, nitroglycerin, and morphine sulfate are the most effective pain relievers. Reperfusion therapy is indicated for patients with ST-segment elevation or a new LBBB with symptoms lasting 12 hours or less. MI treatment may be divided into two paths depending on whether the patient has a STEMI or an NSTEMI. The pharmacologic MI treatment is further subdivided into several groups of medications that improve survival, reduce recurrent ischemic events, and provide symptomatic relief. Following the primary MI treatment, a multimodal regimen of therapies is used. To classify the disease, rapid diagnostic tests and serial biomarker analysis are used to begin MI treatment. The current MI market has been segmented into different commonly used therapeutic classes based on the prevailing MI treatment pattern across the 7MM, which exhibits minor variations in the overall prescription pattern. The major classes covered in the forecast model are antiplatelet agents, anticoagulants, vasodilators, beta-blockers, lipid-lowering drugs, Angiotensin-converting enzyme (ACE) inhibitors, ARBs (Angiotensin-II receptor Blockers), and calcium channel blockers. In recent years, it has been demonstrated that pre-hospital thrombolysis has a role in the management of patients seen early after symptom onset in comparison/association with patients who had primary coronary intervention or elective primary coronary intervention. This is an important issue that is still being researched to prevent cardiac arrest, large scares, and again limit the transition to heart failure and improve the survival rate after AMI. To know more about MI treatment guidelines, visit @ MI Management. MI Pipeline Therapies and Key Companies FARXIGA/FORXIGA (dapagliflozin): AstraZeneca JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company Pelacarsen (TQJ230): Novartis Olpasiran: Amgen Selatogrel: Idorsia Pharmaceuticals FDY-5301: Faraday Pharmaceuticals CSL112: CSL Behring IMT-358: Immediate Therapeutics CL2020: Mitsubishi Chemical Group MEDI6570: AstraZeneca KAND567: Kancera Asundexian: Bayer Dutogliptin: Recardio MPC-25-IC: Mesoblast Learn more about the FDA-approved drugs for MI @ Drugs for MI Treatment. MI Market Dynamics The dynamics of MI market is anticipated to change in the coming years. The growing emphasis on secondary preventive measures to avoid recurrent/new events, lifestyle changes, and the growing number of smokers and cases of obesity, diabetes, hypertension, and others, are expected to fuel MI market growth. Moreover, heart attacks and strokes are major cost drivers in the 7MM healthcare system. The volume of the MI market is enormous. The patient is receiving multiple therapies at the same time. The smallest portion of the patient share can provide pharmaceutical companies with options worth millions of dollars in the MI market. However, several factors are likely to affect the growth of the MI market. Women appear to be underdiagnosed with MI, despite being at higher risk because medical training for healthcare professionals and public information has emphasized the identification of symptoms that typically affect men. This highlights the importance of gender differences in developing strategies for early MI detection and tailored secondary prevention after MI, which should result in a higher rate of MI detection in women. Moreover, off-label therapies and generics account for the majority of the current MI market because they are less expensive and more easily accessible to patients, thus, causing a dip in the MI market growth. Hence, all these factors mentioned above will hamper the MI market growth in the future. Scope of the MI Market Report Therapeutic Assessment: MI current marketed and emerging therapies MI Market Dynamics: MI market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, MI Market Access and Reimbursement Discover more about MI drugs in development @ MI Clinical Trials. Table of Contents Related Reports MI Pipeline MI Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key MI companies, including CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, among others. MI Epidemiology Forecast MI Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted MI epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Myocarditis Pipeline Myocarditis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myocarditis companies, including Cantargia AB, Cardiol Therapeutics, Apitope, among others. Dilated Cardiomyopathy Pipeline Dilated Cardiomyopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dilated cardiomyopathy companies, including Longeveron, Bristol Myers Squibb, Berlin Cures, Tenaya Therapeutics, Cardior Pharmaceuticals, among others. Cardiac Biomarkers Testing Market Cardiac Biomarkers Testing Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cardiac biomarkers testing companies, including Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, among others. Dilated Cardiomyopathy Epidemiology Dilated Cardiomyopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted dilated cardiomyopathy epidemiology in the 7MM. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Upcoming Cardiovascular Diseases Drugs Key Companies in the Cardiology Segment Heart Failure Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on: LinkedIn | Facebook | Twitter. Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services. Logo - Contact Us: Shruti Thakur [email protected] +1(919)321-6187 SOURCE DelveInsight Business Research, LLP

临床3期快速通道

100 项与 Nafimestrocel 相关的药物交易

登录后查看更多信息